Get the Stockscreener App
14.66
2.52%
0.36
After Hours:
14.66
Theravance Biopharma Inc stock is traded at $14.66, with a volume of 393.27K.
It is up +2.52% in the last 24 hours and up +0.41% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$14.30
Open:
$14.31
24h Volume:
393.27K
Relative Volume:
0.99
Market Cap:
$738.30M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-15.93
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
+2.66%
1M Performance:
+0.41%
6M Performance:
+50.05%
1Y Performance:
+77.91%
1-Day Range:
$14.11
$14.70
1-Week Range:
$13.95
$14.70
52-Week Range:
$7.90
$15.15
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
14.66 | 720.17M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Can Theravance Biopharma Inc. stock deliver consistent earnings growthJuly 2025 Momentum & AI Powered Market Trend Analysis - newser.com
Can Theravance Biopharma Inc. stock attract ESG capital inflowsPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Will a bounce in Theravance Biopharma Inc. offer an exitQuarterly Performance Summary & Low Risk High Win Rate Picks - newser.com
What to expect from Theravance Biopharma Inc. in the next 30 daysIPO Watch & Weekly Chart Analysis and Trade Guides - newser.com
How to escape a deep drawdown in Theravance Biopharma Inc.2025 Earnings Impact & Weekly Top Gainers Trade List - newser.com
Can Theravance Biopharma Inc. (0TB) stock sustain revenue momentumMarket Risk Report & Reliable Entry Point Trade Alerts - newser.com
Why Theravance Biopharma Inc. (0TB) stock remains stableJuly 2025 Volume & Expert Approved Momentum Ideas - newser.com
Will Theravance Biopharma Inc. stock see insider buyingIPO Watch & Weekly High Return Stock Opportunities - newser.com
Can Theravance Biopharma Inc. (0TB) stock hit consensus price targetsIndex Update & Fast Exit/Entry Strategy Plans - newser.com
Is Theravance Biopharma Inc. (0TB) stock a momentum leaderPortfolio Gains Summary & AI Optimized Trading Strategy Guides - newser.com
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? - sharewise.com
What consensus target says about Theravance Biopharma Inc. (0TB) stockPortfolio Update Summary & Daily Stock Trend Watchlist - newser.com
Why Theravance Biopharma Inc. (0TB) stock benefits from AI revolutionWeekly Loss Report & Weekly High Return Forecasts - newser.com
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System - Lelezard
Theravance Biopharma Inc. stock trendline breakdown2025 Retail Activity & High Accuracy Swing Entry Alerts - newser.com
Can Theravance Biopharma Inc. stock maintain operating marginsMarket Risk Analysis & Verified High Yield Trade Plans - newser.com
Why Theravance Biopharma Inc. stock is in analyst buy zoneStop Loss & Momentum Based Trading Signals - newser.com
What indicators show strength in Theravance Biopharma Inc.Market Growth Review & Verified Technical Trade Signals - newser.com
Theravance Biopharma Inc. stock retracement – recovery analysisJuly 2025 Reactions & Weekly Hot Stock Watchlists - newser.com
Theravance Biopharma, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges - Markets Mojo
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - Lelezard
Theravance Biopharma (NASDAQ: TBPH) schedules Nov 10 results call at 5 pm EST - Stock Titan
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):